Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Ebola: Hemorrhagic Fever and Macrophage Activation Syndrome

W. Winn Chatham, MD, & Randy Q. Cron, MD, PhD  |  Issue: December 2014  |  

 

ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Cron
Dr. Cron

Randy Q. Cron, MD, PhD, is professor of pediatrics and medicine and the inaugural holder of the Arthritis Foundation, Alabama chapter–endowed chair in Pediatric Rheumatology, and he is the division director and the fellowship director of Pediatric Rheumatology at the University of Alabama at Birmingham. His laboratory studies CD4 T cell transcription as it relates to systemic lupus erythematosus and to HIV-1 infection, as well as genetic mutations associated with macrophage activation syndrome that lead to decreased cytolytic function of lymphocytes.

 

ADVERTISEMENT
SCROLL TO CONTINUE

Disclosures

Dr. Cron has previously served as a consultant to Swedish Orphan Biovitrum, receiving less than $5,000.

References

  1. Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014 Sep 23.
  2. Carroll SA, Towner JS, Sealy TK, et al. Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J Virol. Mar 2013;87(5):2608–2616.
  3. Stahelin RV. Membrane binding and bending in Ebola VP40 assembly and egress. Front Microbiol. 2014;5:300.
  4. Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol. 2014 Jun;10(6):781–790.
  5. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003 Dec;163(6):2371–2382.
  6. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011 Mar 5;377(9768):849–862.
  7. Feldmann H. Ebola–a growing threat? N Engl J Med. Oct 9 2014;371(15):1375–1378.
  8. Stroher U, West E, Bugany H, et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol. 2001 Nov;75(22):11025–11033.
  9. Wahl-Jensen V, Kurz S, Feldmann F, et al. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis. 2011 Oct;5(10):e1359.
  10. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome. J Infect Dis. 2014 Aug 15;210(4):558–566.
  11. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol. 2001 Jun;124(3):453–460.
  12. Barut S, Dincer F, Sahin I, et al. Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: Can it be a new severity criterion? Int J Infect Dis. 2010 Jan;14(1):e50–e54.
  13. van de Weg CA, Huits RM, Pannuti CS, et al. Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbances. PLoS Negl Trop Dis. 2014 Oct;8(10):e3214.
  14. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–246.
  15. Karti SS, Odabasi Z, Korten V, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis. 2004 Aug;10(8):1379–1384.
  16. Tan LH, Lum LC, Omar SF, Kan FK. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol. 2012 Sep;55(1):79–82.
  17. Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012 Jun;13(4):289–298.
  18. Pal P, Giri PP, Ramanan AV. Dengue associated hemophagocytic lymphohistiocytosis: A case series. Indian Pediatr. 2014 Jun;51(6):496–497.
  19. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014 Apr;28(2):277–292.
  20. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507–1517.
  21. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology (Oxford). 2011 Feb;50(2):417–419.
  22. Opal SM, Fisher CJ Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997 Jul;25(7):1115–1124.
  23. Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. 2014 Sep;26(5):562–569.
  24. Bakir M, Ugurlu M, Dokuzoguz B, et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: A multicentre study of clinical features and outcome measures. J Med Microbiol. 2005 Apr;54(Pt 4):385–389.
  25. Yacoub S, Wills B. Predicting outcome from dengue. BMC Med. 2014 Sep 4;12(1):147.
  26. Rathakrishnan A, Klekamp B, Wang SM, et al. Clinical and immunological markers of dengue progression in a study cohort from a hyperendemic area in Malaysia. PLoS One. 2014;9(3):e92021.
  27. Santhosh VR, Patil PG, Srinath MG, et al. Sonography in the diagnosis and assessment of dengue fever. J Clin Imaging Sci. 2014;4:14.
  28. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis. Feb 1999;179 Suppl 1:S1–S7.
  29. Bicakci Z, Tavil B, Tezer H, et al. Hemophagocytosis in a case with Crimean-Congo hemorrhagic fever and an overview of possible pathogenesis with current evidence. Turk J Pediatr. 2013 May–Jun;55(3):344–348.
  30. Ahmed A, Alvi AH, Butt A, et al. Assessment of dengue fever severity through liver function tests. J Coll Physicians Surg Pak. 2014 Sep;24(9):640–644.
  31. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007 Nov 15;196 Suppl 2:S364–371.
  32. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010 Sep;49(9):1645–1653.
  33. Yilmaz G, Koksal I, Topbas M, et al. The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: Severity prediction criteria. J Clin Virol. Apr 2010;47(4):361–365.
  34. Ho TS, Wang SM, Lin YS, et al. Clinical and laboratory predictive markers for acute dengue infection. J Biomed Sci. 2013;20:75.
  35. Suharti C, van Gorp EC, Setiati TE, et al. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost. Jan 2002;87(1):42–46.
  36. Deveci K, Oflaz MB, Sancakdar E, et al. Evaluation of the serum levels of soluble IL-2 receptor and endothelin-1 in children with Crimean-Congo hemorrhagic fever. APMIS. Jul 2014;122(7):643–647.
  37. Valero N, Larreal Y, Espina LM, et al. Elevated levels of interleukin-2 receptor and intercellular adhesion molecule 1 in sera from a Venezuelan cohort of patients with dengue. Arch Virol. 2008;153(1):199–203.
  38. Homchampa P, Sarasombath S, Suvatte V, et al. Natural killer cells in dengue hemorrhagic fever/dengue shock syndrome. Asian Pac J Allergy Immunol. Dec 1988;6(2):95–102.
  39. Zhang M, Behrens EM, Atkinson TP, et al. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. 2014;16(9):439–446.
  40. Walter CT, Barr JN. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol. Nov 2011;92(Pt 11):2467–2484.
  41. Rodriguez-Roche R, Gould EA. Understanding the dengue viruses and progress towards their control. Biomed Res Int. 2013;2013:690835.
  42. Dilber E, Cakir M, Erduran E, et al. High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever. Trop Doct. Jan 2010;40(1):27–30.
  43. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. Sep 1992;4(5):353–360.
  44. Behrens EM, Kreiger PA, Cherian S, et al. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. Oct 2006;33(10):2081–2084.
  45. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. Jul 2003;74(1):85–94.

Related Articles

    New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis

    Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…